Sou Hu Cai Jing·2025-12-18 12:03Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chunli Medical (688236) as of December 18, 2025, showing a slight decline in stock price and mixed capital flow [1][2] - Chunli Medical reported a main revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [2] - The net profit attributable to shareholders for the same period was 192 million yuan, up 213.21% year-on-year, with a non-recurring net profit of 181 million yuan, increasing by 311.07% [2] Group 2 - In Q3 2025, Chunli Medical achieved a single-quarter main revenue of 268 million yuan, reflecting a year-on-year growth of 109.51% [2] - The single-quarter net profit attributable to shareholders was 77.06 million yuan, marking a significant increase of 531.12% year-on-year, while the non-recurring net profit reached 74.52 million yuan, up 439.4% [2] - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan, alongside a gross margin of 67.27% [2] Group 3 - The stock has received ratings from 9 institutions in the last 90 days, with 8 buy ratings and 1 hold rating, and the average target price set at 31.8 yuan [2] - On December 18, 2025, the stock closed at 23.94 yuan, with a turnover rate of 0.32% and a trading volume of 9143 hands, resulting in a transaction amount of 21.97 million yuan [1] - The capital flow data indicates a net outflow of 1.1464 million yuan from main funds, accounting for 5.22% of the total transaction amount, while retail investors saw a net inflow of 2.0827 million yuan, representing 9.48% of the total [1]